Sustainability | February 22, 2022
AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers
New inhalers would have near-zero Global Warming Potential propellant
New inhalers would have near-zero Global Warming Potential propellant
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Resolv ER may remedy leading causes of blindness in adults
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The entire integration and transition of the brands is expected to be completed by March 2022
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
Subscribe To Our Newsletter & Stay Updated
